Amgen (NASDAQ:AMGN) Given New $347.00 Price Target at Guggenheim

Amgen (NASDAQ:AMGN) had its target price increased by Guggenheim from $305.00 to $347.00 in a report released on Friday morning,Benzinga reports. Guggenheim currently has a neutral rating on the medical research company’s stock.

AMGN has been the topic of several other research reports. HSBC reaffirmed a “buy” rating and set a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday. DZ Bank increased their target price on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. Finally, UBS Group increased their price objective on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average target price of $351.65.

Amgen Stock Performance

Shares of AMGN stock opened at $384.20 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $334.45 and a two-hundred day simple moving average of $311.45. Amgen has a 12 month low of $261.43 and a 12 month high of $385.12. The firm has a market capitalization of $206.88 billion, a PE ratio of 27.00, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the company earned $5.31 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts forecast that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is 66.90%.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC lifted its stake in shares of Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after buying an additional 6,676,575 shares in the last quarter. Norges Bank bought a new stake in Amgen during the 2nd quarter valued at $1,663,726,000. Capital World Investors raised its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. Vanguard Group Inc. lifted its position in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI grew its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.